Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth
- PMID: 6572905
- PMCID: PMC393412
- DOI: 10.1073/pnas.80.2.529
Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth
Abstract
A monoclonal antibody directed against a cell surface chondroitin sulfate proteoglycan of human melanoma cells, 9.2.27, and its diphtheria toxin A chain (DTA) conjugate were investigated for their effects on in vitro protein synthesis and in vivo tumor growth of human melanoma cells. The 9.2.27 IgG and its DTA conjugate display similar serological activities against melanoma target cells but only the conjugate can induce consistent in vitro inhibition of protein synthesis and toxicity in M21 melanoma cells. However, both 9.2.27 IgG and its DTA conjugate effect significant suppression of M21 tumor growth in vivo in an immunotherapy model of a rapidly growing tumor in athymic nu/nu mice, suggesting that other host mechanisms may mediate monoclonal antibody-induced tumor suppression.
Similar articles
-
Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo.Proc Natl Acad Sci U S A. 1983 Sep;80(17):5407-11. doi: 10.1073/pnas.80.17.5407. Proc Natl Acad Sci U S A. 1983. PMID: 6577434 Free PMC article.
-
Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice.Proc Natl Acad Sci U S A. 1988 Feb;85(4):1189-93. doi: 10.1073/pnas.85.4.1189. Proc Natl Acad Sci U S A. 1988. PMID: 3422487 Free PMC article.
-
Pharmacokinetics and mechanism of action of a doxorubicin-monoclonal antibody 9.2.27 conjugate directed to a human melanoma proteoglycan.J Natl Cancer Inst. 1988 Sep 21;80(14):1154-9. doi: 10.1093/jnci/80.14.1154. J Natl Cancer Inst. 1988. PMID: 3261803
-
Melanoma: the development of immunoconjugates from a preclinical viewpoint.Immunol Ser. 1990;53:297-316. Immunol Ser. 1990. PMID: 2100562 Review. No abstract available.
-
Production and characterization of monoclonal antibodies directed against connective tissue proteoglycans.Fed Proc. 1985 Feb;44(2):386-93. Fed Proc. 1985. PMID: 2578417 Review.
Cited by
-
Diagnostic and therapeutic use of monoclonal antibodies to human tumor antigens.Med Oncol Tumor Pharmacother. 1984;1(3):143-7. doi: 10.1007/BF02934135. Med Oncol Tumor Pharmacother. 1984. PMID: 6400036 Review.
-
Selective in vitro toxicity of purothionin conjugated to the monoclonal antibody 225.28S to a human high-molecular-weight melanoma-associated antigen.Cancer Immunol Immunother. 1983;15(3):206-9. doi: 10.1007/BF00199166. Cancer Immunol Immunother. 1983. PMID: 6555062 Free PMC article.
-
Immunotoxins against solid tumors.J Cancer Res Clin Oncol. 1988;114(4):385-93. doi: 10.1007/BF02128183. J Cancer Res Clin Oncol. 1988. PMID: 3045130 Free PMC article. Review.
-
Enhanced diagnostic potential of CSPG4 in melanoma and nevi: a comparative study with PRAME, CDC7 and Ki67.J Pathol. 2025 Sep;267(1):69-78. doi: 10.1002/path.6450. Epub 2025 Jul 23. J Pathol. 2025. PMID: 40700516 Free PMC article.
-
Unexpected expression of the 250 kD melanoma-associated antigen in human sarcoma cells.Br J Cancer. 1986 Jun;53(6):839-41. doi: 10.1038/bjc.1986.142. Br J Cancer. 1986. PMID: 3718838 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials